Last reviewed · How we verify

Low dose prednisolone

Post Graduate Institute of Medical Education and Research, Chandigarh · FDA-approved active Small molecule Quality 5/100

Low dose prednisolone is a Small molecule drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh. It is currently FDA-approved.

At a glance

Generic nameLow dose prednisolone
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Low dose prednisolone

What is Low dose prednisolone?

Low dose prednisolone is a Small molecule drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh.

Who makes Low dose prednisolone?

Low dose prednisolone is developed and marketed by Post Graduate Institute of Medical Education and Research, Chandigarh (see full Post Graduate Institute of Medical Education and Research, Chandigarh pipeline at /company/post-graduate-institute-of-medical-education-and-research-chandigarh).

What development phase is Low dose prednisolone in?

Low dose prednisolone is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing